VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist;Estudio VARIAR: VAloración de la eficacia y seguridad a corto plazo en artritis reumatoide del uso de RItuximab comparado con Antagonistas del factor de necrosis tumoral alfa en segunda línea terapéutica en pacientes con artritis reumatoide Refractarios a un primer antagonista del factor de necrosis tumoral alfa

Reumatologia Clinica

Volumn 12, Issue 6, 2016, Pages 319-322

  Torrente Segarra, Vicenç ^a   Acosta Pereira, Asunción ^b   Morla, Rosa ^c   Ruiz, José Miguel ^d   Clavaguera, Teresa ^e   Figuls, Ramon ^a   Corominas, Hector ^a   Geli, Carme ^b   Roselló, Rosa ^f   de Agustín, Juan José ^g   Alegre, Cayetano ^g   Pérez, Carolina ^h   García, Angel ⁱ   Rodríguez de la Serna, Arturo ^b  

^a HOSPITAL GENERAL DE CATALUNYA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Hospital Del Vendrell   (Spain)

^d HOSPITAL DE VILADECANS   (Spain)

^e Hospital de Palamos   (Spain)

^f HOSPITAL SAN JORGE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h Hospital de Mollet   (Spain)

ⁱ HOSPITAL DE TORREVIEJA   (Spain)

Author keywords

Anti TNF alpha; Rheumatoid arthritis; Rituximab

Indexed keywords

RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB;

ARTICLE; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84955584899     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2015.11.019     Document Type: Article

References (15)

1. 1 Carmona, L., Villaverde, V., Hernández-García, C., Ballina, J., Gabriel, R., Laffon, A., EPISER StudyGroup. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 41 (2002), 88–95.
2. 2 Furst, D.E., Keystone, E.C., Fleischmann, R., Mease, P., Breedveld, F.C., Smolen, J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 1 (2010), 2–29.
3. 3 Tornero Molina, J., Sanmartí Sala, R., Rodríguez Valverde, V., Martín Mola, E., Marenco de la Fuente, J.L., González Álvaro, I., et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 6 (2010), 23–36.
4. 4 Salliot, C., Finckh, A., Katchamart, W., Lu, Y., Sun, Y., Bombardier, C., et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: A meta-analysis. Ann Rheum Dis. 70 (2011), 266–271.
5. 5 Finckh, A., Ciurea, A., Brulhart, L., Kyburz, D., Möller, B., Dehler, S., et al. Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis, B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 56 (2007), 1417–1423.
6. 6 Favalli, E.G., Biggioggero, M., Marchesoni, A., Meroni, P.L., Survival on treatment with second-line biologic therapy: A cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 53 (2014), 1664–1668.
7. 7 Emery, P., Gottenberg, J.E., Rubbert-Roth, A., Sarzi-Puttini, P., Choquette, D., Taboada, V.M., et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 74 (2015), 979–984.
8. 8 Soliman, M.M., Hyrich, K.L., Lunt, M., Watson, K.D., Symmons, D.P., Ashcroft, D.M., British Society for Rheumatology Biologics Register. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 64 (2012), 1108–1115.
9. 9 Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988), 315–324.
10. 10 Disponible en: http://www.ser.es/wp-content/uploads/2015/09/GUIPCAR_2011_V7_definitiva.pdf [consultado 30 Dic 2015].
11. 11 Esteve-Vives, J., Batlle-Gualda, E., Reig, A., Spanish version of the Health Assessment Questionnaire: Reliability, validity and transcultural equivalency. Grupo para la Adaptación del HAQ a la Población Española. J Rheumatol. 20 (1993), 2116–2122.
12. 12 Funovits, J., Aletaha, D., Bykerk, V., Combe, B., Dougados, M., Emery, P., et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological report phase I. Ann Rheum Dis. 69 (2010), 1589–1595.
13. 13 Finckh, A., Ciurea, A., Brulhart, L., Möller, B., Walker, U.A., Courvoisier, D., et al. Arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis. 69 (2010), 387–393.
14. 14 Gomez-Reino, J.J., Maneiro, J.R., Ruiz, J., Roselló, R., Sanmarti, R., Romero, A.B., MIRAR Study Group. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study. Ann Rheum Dis. 71 (2012), 1861–1864.
15. 15 Finckh, A., Möller, B., Dudler, J., Walker, U.A., Kyburz, D., Gabay, C., Physicians of the Swiss Clinical Quality Management for Rheumatoid Arthritis; physicians of SCQM-RA. Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Ann Rheum Dis. 71 (2012), 1680–1685.